TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, TScan Therapeutics Inc (TCRX) does not present a strong buy opportunity for a beginner investor with a long-term strategy. While there are some positive indicators such as hedge fund buying and a raised price target by analysts, the company's financial performance is weak, with significant net income and EPS declines. Additionally, there are no strong technical signals or recent news catalysts to support an immediate buy decision. Holding off for now may be prudent.
The MACD is positive and contracting, indicating a mild bullish momentum. RSI is neutral at 53.277, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 1.21, with resistance at 1.39 and support at 1.031.
Hedge funds are significantly increasing their buying activity, with a 12447.81% increase over the last quarter. Analysts have raised the price target to $5 and maintained an Outperform rating.
The company's financial performance shows a significant decline in net income (-35.83% YoY) and EPS (-40.00% YoY). No recent news or congress trading data is available to act as a catalyst.
In Q4 2025, revenue increased by 286.02% YoY to $2,567,000. However, net income dropped to -$22,977,000 (-35.83% YoY), and EPS fell to -0.18 (-40.00% YoY). Gross margin remained stable at 100%.
Wedbush raised the price target from $4 to $5 and maintained an Outperform rating, citing upcoming trial results in 2026 as a potential catalyst.
